The new anticoagulants

Perspectives in Vascular Surgery and Endovascular Therapy

Volumn 19, Issue 3, 2007, Pages 332-335

  Stone, William M ^a   Tonnessen, Britt H ^a   Money, Samuel R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anticoagulants; Direct thrombin inhibitors; Fondaparinux; Idraparinux; Metapentasaccharides; Ximelagatran

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; IDRAPARINUX; OLIGOSACCHARIDE; PYRIDINE DERIVATIVE; THROMBIN; WARFARIN;

DRUG ANTAGONISM; HUMAN; REVIEW;

ANTICOAGULANTS; ANTITHROMBIN III; BENZIMIDAZOLES; HUMANS; OLIGOSACCHARIDES; PYRIDINES; THROMBIN; WARFARIN;

EID: 38449123800     PISSN: 15310035     EISSN: 15310027     Source Type: Journal    
DOI: 10.1177/1531003507304441     Document Type: Article

References (17)

1. Hirsh J, Hoak J. Management of deep venous thrombosis and pulmonary embolism: a statement for healthcare professionals from the Council on Thrombosis. Circulation. 1996;93:2212-2245.
2. Duxbury BM, Poller L. The oral anticoagulant saga: past present, and future. Clin Appl Thromb Hemost. 2001;7: 269-275.
3. Halperin JL, Executive Steering Committee. SPORTIF III and V Study Investigators. Ximelagatran compound with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 2003;146:431-438.
4. Turpie ACG, Bauer KA, Eriksson BI, Lassen MR for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs. enoxaprin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of four randomized double blinded studies. Arch Int Med. 2002;162:1833-1840.
5. Koopman MM, Buller HR. Short and long-acting synthetic pentasaccharides. J Int Med. 2003;254:335-342.
6. Idraparinux sodium: SANORG 34006, SR34006. Drugs R D;5:164-165.
7. The PERSIST investigators: A novel long-acting synthetic factor Xa inhibitor (SanOrg 34006) to replace warfarin for secondary prevention of deep venous thrombosis. A Phase II evaluation. J Thromb Haemost. 2004;2:47-53.
8. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaprin for prevention of VTE after total hip or knee joint replacement. Thromb Haemost. 2003;89:288-296.
9. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of VTE after total knee replacement arthroplasty. Ann Int Med. 2002;137:648-655.
10. Olsson SB. Executive Steering Committee on behalf of SPORTIF III Investigators. Stroke prevention with oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003;362:1691-1698.
11. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of Ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349:1703-1712.
12. Mungall D. BIBR-1048 Boehringer Ingelheim. Curr Opin Investig Drugs. 2002;3:905-907.
13. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran extenilate, compared with enoxaprin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost. 2005;3:103-111.
14. RE-MOBILIZE: a phase III study investigating the efficacy and safety of two different dose regimines of dabigatran extenilate compared to enoxaprin in prevention of venous thromboembolism in patients with primary elective total knee replacement. Available at: http://www .clinicaltrials.gov/ct/gui/show/ NCTDOI52971. Accessed November 20, 2005.
15. Alexander JH, Young H, Becker RC, et al. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS trial. J Thromb Haemost. 2005;3:439-447.
16. Huisman MV, Borris LC, Dahl OE, et al. An oral, direct, factor Xa inhibitor, rivaroxaban: once daily regimen for thromboprophylaxis after hip replacement. Pathophysiol Haemost Thromb. 2006;35:A1.
17. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmocodynamics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61: 873-880.